Introduction {#sec1}
============

Tuberculosis (TB) is a pre-historic disease caused by *Mycobacterium tuberculosis* (MTB) ([@bib19]). Although there are more than 150 species of *Mycobacterium* sp., MTB is still the most dominant and prevailing member of this genus all over the world, accounting for 10 million deaths in 2019 ([@bib17]).

The World Health Organization (WHO) declared TB as a global emergency in 1993 (Grange and Zumla [@bib5]). Despite significant medical and social interventions, TB consistently affects vulnerable populations across the world and remains a leading global public health problem. Treatment of drug-susceptible TB takes six months while treatment of rifampicin-resistant TB (RR-TB) and multidrug-resistant TB (MDR-TB) requires a long therapy for up to two years ([@bib17]).

Globally, an 85% successful treatment rate has been reported for drug-susceptible MTB. The emergence of drug resistance, however, still poses a threat to global efforts. The WHO estimated 10.4 million new TB cases consist of 490 000 multidrug-resistant TB and 110 000 rifampicin-resistant TB. Five countries such as India, China, Indonesia, Philippines, and Pakistan are accounting for 56% of TB burden. Despite the development of rapid molecular tools, only 37% of MDR-TB were reported globally which shows laboratory gaps. China, India, and Russia reported 47% of the total global MDR/RR-TB cases. Pakistan is a high TB endemic country, standing at 5^th^ position in the list of 30 high burden countries (HBC) with an estimated 518 000 TB cases including 15 000 MDR-TB. The estimated proportion of MDR-TB is 4.2% in new patients and 16% in the previously treated patients ([@bib17]). According to the drug resistance survey conducted in 2012, the prevalence of MDR-TB was 3.7% in newly diagnosed TB cases and 18.1% among previously treated TB cases ([@bib14]). KPK is one of the four provinces of Pakistan that contributes a proportion of 11.9% in the total national population with an estimated 270 TB cases per 100 000 population ([@bib10]). Patients with drug-susceptible TB receive anti-TB treatment for at least six months while patients with MDR-TB and RR-TB receive longer treatments comprising of second-line drug regimens ([@bib11]). The sputum smear microscopy is used as an initial screening test for TB diagnosis, while GeneXpert assays are employed for the rapid detection of RR-TB at the district level ([@bib11]). In the current study, we analyzed the prevalence of MDR-TB among different lineages prevalent in the Khyber Pakhtunkhwa (KPK) province of Pakistan. MDR-TB is notified after a confirmatory DST test performed at the central BSL-III laboratory.

Experimental {#sec2}
============

Material and Methods {#sec3}
--------------------

**Study site**. Random samples were collected from 25 districts of KPK using a simple random sampling (SRS) formula, which was previously used in a national TB survey of Pakistan: $${n{\left( {SRS} \right)}} = \frac{N \times z^{2} \times p \times \left( {1 - p} \right)}{{d^{2} \times \left( {N - 1} \right)} + {z^{2} \times p \times \left( {1 - p} \right)}}$$where

1.  SRS -- Sample Random Sampling

2.  N -- total number of new smear positive cases registered in the lab

3.  z -- z-value (from the standard normal distribution) that corresponds to the desired confidence level

4.  d -- absolute precision

5.  p -- expected proportion of MDR patient in the target population

**Study participants and sample collection**. A total of 1969 positive *M. tuberculosis* cases were calculated using this SRS formula. To achieve the target samples a total of 5759 clinical samples were collected from 25 districts and were diagnosed for TB. The patients' data were collected from their parents or the next caretakers.

**Sputum processing**. All received samples were digested and decontaminated using standard N-acetyl-L-cysteine sodium hydroxide (NALC-NaOH) method ([@bib4]) in a biosafety level 3 laboratory (BSLIII) at the Provincial TB Reference Laboratory, Peshawar. Briefly, one aliquot was inoculated on the Lowenstein Jensen medium (LJ) and in a Mycobacterium growth indicator tube (MGIT). Positive growth in the tubes was confirmed by Tbc ID device (Ref: 245159, Becton, Dickinson).

**Drug susceptibility testing (DST)**. All confirmed mycobacterial isolates were processed for both phenotypic DST and molecular resistance assay. DST was performed using a BD BACTEC MGIT 960 SIRE kit (Ref: 245123, Becton, Dickinson), in which the final drug concentration was 1 μg/ml for RIF, and 0.1 μg/ml for INH. One sample aliquot was processed for acid-fast bacilli (AFB) microscopy using Primostar-LED fluorescent microscopy.

**Data analysis**. Results were recorded in the local laboratory management information software and analyzed using SPSS V.15 (IBM, USA). Sensitivity and specificity were calculated using Medcalc software (<https://www.medcalc.org>).

Results {#sec4}
=======

Among 5759 TB suspects, 1969 (34%) were culture-positive, 3121 (54%) were culture-negative, and 344 (6%) were contaminated. The proportion of TB was higher in females (39%) than males (29%), thus, a strong association was observed between the gender and tuberculosis disease (χ (3) = 68.2, *p* = 0.001). It was observed that the age group of 25--34 years was more likely infected with TB (40%) when compared to other groups (Table [I](#tbl1){ref-type="table"}). The susceptibility testing towards the first-line drugs as rifampicin, isoniazid, ethambutol, streptomycin, and pyrazinamide was performed on 1969 culture-positive isolates.

###### 

Association of TB with gender, different age groups and treatment history, *p*-value of \< 0.05 shows a statistical significance.

![](pjm-69-2-133-t001)

  Character                                 TB Suspects   Positive cases   *p*-value
  ----------------------------------------- ------------- ---------------- ----------------------------------
  Gender                                                                   
  Male                                      3189          947 (29%)        χ (3) = 68.2, *p* = 0.005
  Female                                    2570          1022 (39%)       
  Age group                                                                
  01--14                                    437           96 (22%)         
  15--24                                    1137          396 (34%)        
  25--34                                    1180          473 (40%)        
  35--44                                    827           298 (26%)        
  45--54                                    732           227 (31%)        
  55--64                                    819           282 (34.4%)      
  65--100                                   627           197 (31.4%)      
  Treatment history                                                        
  Previously Treated                        1024          461 (45%)        χ (3) = 68, *p*-value = 0.05
  Never Treated                             3922          1508 (38%)       
  Disease type                                                             
  Pulmonary                                 5290          1864 (35%)       χ (3) = 68, *p*-value \< 0.05
  Extra Pulmonary                           469           105 (22%)        
  Sample type                                                              
  Ascetic Fluid                             91            10 (11%)         χ (36) = 259.6, *p*-value ≤ 0.05
  BAL^[\*](#FNt1){ref-type="table-fn"}^     172           45 (26%)         
  Bone                                      20            2 (10%)          
  CSF^[\*\*](#FNt2){ref-type="table-fn"}^   44            2 (5%)           
  Gastric Lavage                            68            5 (7%)           
  Lymph Node                                10            3 (30%)          
  Pericardial fluid                         26            3 (12%)          
  Pleural Fluid                             172           26 (15%)         
  Pus                                       54            9 (17%)          
  Sputum                                    5033          1858 (37%)       
  Synovial Fluid                            3             0 (0%)           
  Tissue                                    20            5 (25%)          
  Urine                                     46            1 (2%)           

Bronchoscopy alveolar lavages,

Cerebrospinal fluid

DST results of 1969 isolates showed that 238 (12%) isolates were resistant to at least one drug, while 97 (4.9%) were confirmed to be MDR-TB. The remaining 1731 (88%) isolates were sensitive to all drugs. The drug resistance was the highest to streptomycin in 173 (9%) isolates, followed by isoniazid in 119 (6%), ethambutol in 101 (5%), rifampicin in 99 (5%), and pyrazinamide in 65 (3%) isolates.

The drug resistance found was correlated with different factors from the patient history including age, gender, and treatment history. MDR was observed in 61 (5.2%) males and 36 (4.5%) in female patients. No significant association of MDR with gender (χ (1) = 1, *p*-value = 0.26) or age group (χ (5.8) = 6, *p*-value = 0.44) was observed. The prevalence of MDR was higher in the age group of 55--64 years (6.4%), followed by a group of 15--24 years (6%) (Table [II](#tbl2){ref-type="table"}). MDR correlation with pulmonary and extra-pulmonary TB was also analyzed and it was found that the prevalence of MDR in pulmonary TB was significantly higher 94 (5.3%) when compared to extra-pulmonary TB (1.5%), χ (5.3) = 1, *p*-value = 0.009. The resistance of the MTB isolates from the previously treated patients was significantly higher in 48 (10.4%) cases when compared to 49 (3.2%) untreated patients. It can indicate an association of drug resistance with the patient treatment history (χ (16) = 2, *p*-value = 0.001).

###### 

Correlation of the MDR-TB prevalence with patient's age, gender, and previous treatment history.

![](pjm-69-2-133-t002)

  Character                                Total DST   Diagnosed with DR-TB   *p*-value
  ---------------------------------------- ----------- ---------------------- --------------------------------
  Gender                                                                      
  Male                                     1167        61 (5.2%)              χ (1) = 1, *p* = 0.26
  Female                                   800         36 (4.5%)              
  Age group                                                                   
  01--14                                   186         5 (2.6%)               χ (5.8) = 6, *p* = 0.445
  15--24                                   333         20 (6%)                
  25--34                                   372         18 (4.8%)              
  35--44                                   279         11 (4%)                
  45--54                                   258         10 (3.8%)              
  55--64                                   294         19 (6.4%)              
  65--100                                  245         14 (5.7%)              
  Treatment history                                                           
  NT^[\*](#FNt3){ref-type="table-fn"}^     1508        49 (3.2%)              χ (16) = 2, *p*-value = 0.001
  PT^[\*\*](#FNt4){ref-type="table-fn"}^   461         48 (10.4%)             
  Disease type                                                                
  Pulmonary                                1771        94 (5.3%)              χ (5.3) = 1, *p*-value = 0.009
  Extra Pulmonary                          196         3 (1.5%)               

NT = Never treated;

PT = previously treated;

DST = drug susceptibility testing; DR-TB = drug resistant tuberculosis

Discussion {#sec5}
==========

MDR-TB is a major threat to public health. Monitoring its trends over time is crucial to prevent further emergence of drug resistance. Surveillance of drug resistance is, therefore, a critical component of any TB control Programme ([@bib18]). A decade back, only 18 422 laboratory-confirmed MDR-TB cases were reported from 104 countries. It escalated to an estimated 490 000 cases in 2016 ([@bib17]). Even today MDR-TB is a persistent threat to the global community but unfortunately, only 47% of MDR cases could be diagnosed among the global estimates due to limited resources and laboratory gaps. Similarly, among all the registered MDR-TB cases, only 54% could be successfully treated. This study provides preliminary data of MDR-TB in KPK, which contributes to 13% of the national TB burden. In this first large-scale data, we found that MDR-TB was detected among 4.9% of newly diagnosed patients. This figure is consistent with the first national DRS of Pakistan where it has been reported 3.7% MDR-TB cases ([@bib14]) and 3.6% the global estimates ([@bib17]). Similar findings from Pakistan reported a 2--5% MDR-TB ratio ([@bib7]; [@bib3]). A comparative high ratio of 29% and 9% MDR-TB was reported in early literature from other areas of Pakistan ([@bib1]; [@bib1]). However, Akhtar et al. demonstrated a much higher MDR ratio of 69% in a study performed in Punjab ([@bib1]). Possible differences in these reports might be due to the variance in study design and sample inclusion criteria. People ages 15 to 34 years old were at high risk to develop MDR-TB ([@bib6]; [@bib1]; [@bib8]). The increased drug resistance in previously treated cases (10.4%) was high as compared to newly diagnosed patients. These findings are consistent with previously published data ([@bib14]). TB has been found to be more prevalent in males ([@bib9]); however, we did not detect a significant correlation of MDR-TB with gender, extra-pulmonary TB or a sample type ([@bib2]; [@bib13]). In contrast to this, data from Africa shows a relatively high prevalence of drug-resistant TB in women ([@bib12]).

In conclusion, MDR-TB is an emerging problem in Khyber Pakhtunkhwa, Pakistan. This study has highlighted the MDR surveillance among the population of a geographically distinct area of Pakistan. Knowing the approximate magnitude of MDR-TB, this study will help for better management of drug resistance towards global TB control 2030.
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